Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab versus triamcinolone for acute gouty arthritis flares
2010-024173-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab and triamcinolone acetonide in gout and acute gout flare (3 arms), sponsored by Novartis. Primary endpoint: Pain intensity in the most affected joint at 72 hours. Started Mar 2011; status: completed.
02
Drugs
canakinumabtriamcinolone acetonide
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2010-024173-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024173-39.